Phase 3 ADD Clinical Trials
46 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 46 trials
Recruiting
Phase 2Phase 3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled493 locationsNCT05987241
Recruiting
Phase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Bladder Cancer
Merck Sharp & Dohme LLC590 enrolled21 locationsNCT07419295
Recruiting
Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled82 locationsNCT06510374
Recruiting
Phase 2Phase 3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary IncontinenceOveractive BladderUrologic Diseases+1 more
Northwestern University66 enrolled1 locationNCT05878951
Recruiting
Phase 3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting
Phase 3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled281 locationsNCT07218380
Recruiting
Phase 3
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled66 locationsNCT06545955
Recruiting
Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC641 enrolled193 locationsNCT06319820
Recruiting
Phase 3
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Stage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8Recurrent Non-Muscle Invasive Bladder Carcinoma
Alliance for Clinical Trials in Oncology330 enrolled56 locationsNCT07000084
Recruiting
Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
NRG Oncology486 enrolled211 locationsNCT07097142
Recruiting
Phase 3
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
Bladder CancerUrothelial Carcinoma BladderNeoplasm Recurrence+3 more
Verity Pharmaceuticals Inc.540 enrolled6 locationsNCT05037279
Recruiting
Phase 2Phase 3
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial CancerBladder Cancer
Daiichi Sankyo630 enrolled79 locationsNCT07129993
Recruiting
Phase 3
Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder
Neurogenic Bladder
Centre Hospitalier Universitaire Dijon110 enrolled1 locationNCT06588010
Recruiting
Phase 3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC220 enrolled104 locationsNCT06919965
Recruiting
Phase 2Phase 3
The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's Lesions
Bladder Pain SyndromeICHunner Type Interstitial Cystitis
JSC NextGen180 enrolled1 locationNCT07459790
Recruiting
Phase 2Phase 3
The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis Without Hunner's Lesions.
ICInterstitial Cystitis and Bladder Pain SyndromeInterstitial Cystitis, Chronic
JSC NextGen180 enrolled1 locationNCT07391306
Recruiting
Phase 3
Oxybutynin for Post-surgical Bladder Pain and Urgency
Overactive Bladder SyndromeNeuropathic Bladder
University of California, Davis100 enrolled1 locationNCT03952299
Recruiting
Phase 3
A Study of Surgical Techniques During Cystectomy
Bladder Cancer
Memorial Sloan Kettering Cancer Center530 enrolled7 locationsNCT06703476
Recruiting
Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a.112 enrolled47 locationsNCT05024773
Recruiting
Phase 3
The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
Bladder CancerEndometriosisInterstitial Cystitis+4 more
Centre Hospitalier Universitaire Vaudois232 enrolled4 locationsNCT05726786